News ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Delayed Nasdaq Other stock markets 12:37:53 2024-04-16 pm EDT			5-day change	1st Jan Change
2.03 ^USD	-0.73%		-15.06%	+2.53%

Mar. 14	Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	MT
Mar. 13	ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	Mar. 14	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ProQR Announces Year End 2023 Operating and Financial Results	Mar. 13	GL
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing	Feb. 15	GL
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024	Jan. 19	GL
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	Jan. 05	CI
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration	Jan. 05	GL
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration	Jan. 05	AQ
ProQR Therapeutics Announces Transaction Completed for Thea to Acquire Sepofarsen and Ultevursen Ophthalmic Assets	Dec. 11	AQ
ProQR Therapeutics Completes Divestment of Two Ophthalmic Assets to Laboratoires Thea	Dec. 08	MT
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets	Dec. 08	GL
Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?170 million.	Dec. 06	CI
Raymond James Adjusts ProQR Therapeutics' Price Target to $4 From $5, Keeps Outperform Rating	Nov. 08	MT
Chardan Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $2	Nov. 08	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
ProQR: Q3 Earnings Snapshot	Nov. 07	AQ
ProQR Announces Third Quarter 2023 Operating and Financial Results	Nov. 07	GL
ProQR Therapeutics Granted US Patent Expanding Protection of RNA Editing Technology	Nov. 06	MT
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing	Nov. 06	GL
Stargardt Disease Pipeline, Clinical Trials, Emerging Therapies, and FDA Approvals 2023 (Updated)	23-09-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Summary

Filters